A Post-Synthetic Modification Strategy for the Preparation of Homooligomers of 3-Amino-1-methylazetidine-3-carboxylic Acid
Synlett · 15.09.2023 · 34 (15) · 1787-1790
DOI: 10.1055/a-2071-4122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Synlett, erschienen am 15.09.2023. Verfasst von Dayi Liu und 5 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Agence Nationale de la Recherche, Chinese Scholarship Council.
Abstract (Originalsprache)
Post-synthetic modification is a powerful technique allowing access to noncanonical peptide derivatives in a selective manner, but it has not so far been applied for the installation of multiple arrays of modified side chains. Here, we use this approach in solution phase to prepare short N- and C-capped homooligomers of 3-amino-1-methylazetidine-3-carboxylic acid with all the azetidine side chain functions in free amine form. The key step is the multiple reductive amination reaction of the corresponding post-synthetically deprotected secondary amines.
Förderung
- Agence Nationale de la Recherche
- Chinese Scholarship Council
Zitieren
APA
Liu, D., Imani, Z., Aitken, D. J., Gourson, C., Guillot, R., & Robin, S. (2023). A Post-Synthetic Modification Strategy for the Preparation of Homooligomers of 3-Amino-1-methylazetidine-3-carboxylic Acid. Synlett, 34(15), 1787-1790. https://doi.org/10.1055/a-2071-4122
Vancouver
Liu D, Imani Z, Aitken DJ, Gourson C, Guillot R, Robin S. A Post-Synthetic Modification Strategy for the Preparation of Homooligomers of 3-Amino-1-methylazetidine-3-carboxylic Acid. Synlett. 2023;34(15):1787-1790. doi:10.1055/a-2071-4122
BibTeX
@article{Liu2023,
author = {Liu, Dayi and Imani, Zeynab and Aitken, David J. and Gourson, Catherine and Guillot, Régis and Robin, Sylvie},
title = {A Post-Synthetic Modification Strategy for the Preparation of Homooligomers of 3-Amino-1-methylazetidine-3-carboxylic Acid},
journal = {Synlett},
year = {2023},
volume = {34},
number = {15},
pages = {1787--1790},
doi = {10.1055/a-2071-4122}
}
EUVIMED